The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma

NACompletedINTERVENTIONAL
Enrollment

680

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

April 30, 2020

Study Completion Date

July 31, 2020

Conditions
Bladder Cancer
Interventions
DEVICE

Bladder EpiCheck Urine Test

The Bladder EpiCheck test is an in vitro diagnostic device for the detection of DNA methylation patterns in urine that are associated with bladder cancer. It is intended for use as a noninvasive method for monitoring for tumor recurrence in conjunction with cystoscopy inpatients previously diagnosed with bladder cancer

PROCEDURE

Cystoscopy and pathology

Routine cystoscopy for bladder cancer recurrence and pathology confirmation for patients with positive cystoscopy

Trial Locations (11)

11530

Urological Surgeons of Long Island, Garden City

21237

Chesapeake Urology Research Associates, Baltimore

27710

Duke University Health System, Durham

37232

Vanderbilt University Medical Center, Nashville

44195

Cleveland Clinic, Cleveland

48084

Michigan Institute of Urology, P.C., Troy

55125

Metro Urology, Woodbury

78229

Urology San Antonio, San Antonio

80211

The Urology Center of Colorado, Denver

98195-6158

University Of Washington, Seattle

M5G 1Z5

UHN, Princess Margret Cancer center, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Nucleix Ltd.

INDUSTRY

NCT02700464 - The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma | Biotech Hunter | Biotech Hunter